Position Summary:
Looking for opportunities with purpose, impact and possibilities? Our client, Vertex, is a global biotechnology company that invests in scientific innovation. As they grow their pipeline at pace, they are strengthening their reputation for creating transformative medicines for people with serious diseases.
General Summary:
Vertex are seeking a motivated and enthusiastic organic chemist to join their growing Medicinal Chemistry team as a Research Scientist at the Oxford Site.
We’re preparing the next edition of One Nucleus Highlights—our A4 printed and digital publication launching 9 November 2026, at BIO-Europe.
To reach our life science ecosystem with your expertise, you can submit a thought-leadership piece on a key theme felt to be shaping our industry and wider trends in the sector. Alternatively, you could place an advert to be seen in such a context in the eyes of your key customers.
Why Contribute?
For years, the instinct in drug discovery was simple: when a decision is hard, get more data. But that instinct has stopped paying off. The binding constraint today isn't volume—it’s fragmentation. Our latest white paper explores why the most valuable signals are hiding in the space between datasets that were never built to speak to one another.
Stop collecting and start connecting. Read the full analysis here: https://www.digital-science.com/lp/data-integration-challenge/
In life sciences, "feeling" ready for the future isn’t a strategy—it’s a risk. Are you actually leading the field? Most organizations are busy, but few know if they’re actually keeping pace with their peers.
We’re officially launching The Innovation Readiness Index: a diagnostic designed to stop the guesswork. We benchmark your capabilities across the 5 pillars that matter:
👉 Trust & Outcomes
👉 Governance & Flow
👉 AI Readiness
In early discovery and development, accurate bioanalytical methods, combined with CMC manufacturability, are essential for driving molecule screening and assessing developability within a DMPK/ADME framework.
In this webinar, we will present case studies spanning multiple novel modalities including antibodies, bispecific antibodies, ADC (Antibody Drug Conjugate), and APC (Antibody Peptide Conjugate) therapeutics. The presentation will focus on three key areas:
"We select patients on biology, but we lose them on circumstance."
That single sentence is the reason Luvida’s hosting a dinner.
We obsess over first patient in. But the metric that actually decides whether a trial succeeds is last patient in, and too often we lose people not because the science failed, but because the trial was never designed around the reality of their lives.
Luvida is a London-based company that integrates social determinants of health data to predict and mitigate clinical trial risk.
The Rosalind Franklin Institute (the Franklin) is a technology institute established by the UK Government as a unique centre committed to advancing tools that are needed to transform healthcare in the future. Through a unique integration of disciplines, we will develop disruptive new technologies designed to tackle major challenges in health and life science. This will accelerate the discovery of new treatments for chronic diseases affecting millions of people around the world.
As our sector continues to navigate change, we’re committed to creating accessible learning opportunities that support our community. Explore our latest courses and webinars, designed to help professionals at every career stage grow, connect, and thrive.
________________________________________________
Spotlight: One Nucleus September Training
Last Chance to Register!
Fierce Biotech at London Life Sciences Week is a one-day event convening 200-250 leaders from across
the global biopharma and investment ecosystem. The event centers on scientific innovation, drug development and dealmaking, creating a platform for life science executives, investors and business development leaders to explore cutting-edge science and strategic partnerships.